文献速递白血病造血干细胞移植与细胞治疗

阿西米尼联合达沙替尼和泼尼松治疗费城染色体阳性急性白血病

Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
PubMed 文献 · Blood · 2025-01-01

这项1期研究纳入24例费城染色体阳性急性白血病成人患者,其中急性淋巴细胞白血病22例、慢性髓性白血病淋系急变期2例,评估阿西米尼联合达沙替尼140 mg每日加泼尼松60 mg/m2每日的最大耐受剂量。阿西米尼推荐2期剂量为80 mg每日;在初诊急性淋巴细胞白血病患者中,第28天和第84天完全血液学缓解率分别为84%和100%,第84天100%达到完全细胞遗传学缓解。

要点

  • 阿西米尼推荐2期剂量为80 mg每日,与达沙替尼和泼尼松联合。
  • 160 mg每日的剂量限制性毒性为无症状的3级胰酶升高,无胰腺炎症状。
  • 初诊费城染色体阳性急性淋巴细胞白血病患者第84天完全血液学缓解率100%。

核心结论

  • 达沙替尼与阿西米尼双重BCR::ABL1抑制在初诊费城染色体阳性急性淋巴细胞白血病患者中安全且活性令人鼓舞。

研究设计与样本

  • 1期研究(NCT03595017),纳入24例费城染色体阳性急性白血病成人患者,其中急性淋巴细胞白血病22例(p190 16例,p210 6例),慢性髓性白血病淋系急变期2例。
  • 阿西米尼每日剂量递增联合达沙替尼140 mg每日加泼尼松60 mg/m2每日,以确定最大耐受剂量;28天诱导后达沙替尼和阿西米尼持续 indefinitely 或直至造血干细胞移植。
  • 中位年龄64.5岁(范围33-85岁),50%年龄≥65岁。

主要发现

  • 阿西米尼推荐2期剂量为80 mg每日,与达沙替尼和泼尼松联合。
  • 160 mg每日的剂量限制性毒性为无症状的3级胰酶升高,无胰腺炎症状。
  • 未发生血管闭塞事件。
  • 初诊急性淋巴细胞白血病患者第28天和第84天完全血液学缓解率分别为84%和100%。
  • 第84天,100%患者达到完全细胞遗传学缓解,89%通过多色流式细胞术达到可测量残留病阴性(<0.01%),74%和26%分别达到BCR::ABL1逆转录定量聚合酶链反应<0.1%和<0.01%。

关键数值与推荐

  • 阿西米尼推荐2期剂量为80 mg每日,联合达沙替尼和泼尼松。
  • 160 mg每日时剂量限制性毒性为无症状的3级胰酶升高。
  • 初诊急性淋巴细胞白血病第28天完全血液学缓解率84%,第84天100%。
  • 第84天完全细胞遗传学缓解率100%,可测量残留病阴性率89%。
  • 第84天BCR::ABL1逆转录定量聚合酶链反应<0.1%者为74%,<0.01%者为26%。

临床怎么用

  • 原文结论为达沙替尼与阿西米尼双重BCR::ABL1抑制在初诊费城染色体阳性急性淋巴细胞白血病患者中安全且活性令人鼓舞,未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dasatinib is an effective treatment for Philadelphia chromosome-positive (Ph+) acute leukemia, but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses and prevent the emergence of dasatinib-resistant clones. In this phase 1 study (NCT03595017), 24 adults with Ph+ acute lymphoblastic leukemia (ALL; n = 22; p190, n = 16; p210, n = 6) and chronic myeloid leukemia in lymphoid blast crisis (n = 2) were treated with escalating daily doses of asciminib in combination with dasatinib 140 mg daily plus prednisone 60 mg/m2 daily to determine the maximum tolerated dose. After a 28-day induction, dasatinib and asciminib were continued indefinitely or until hematopoietic stem cell transplant. The median age was 64.5 years (range, 33-85; 50% aged ≥65 years). The recommended phase 2 dose of asciminib was 80 mg daily in combination with dasatinib and prednisone. The dose limiting toxicity at 160 mg daily was asymptomatic grade 3 pancreatic enzyme elevation without symptomatic pancreatitis. There were no vaso-occlusive events. Among patients with de novo ALL, the complete hematologic remission rates at days 28 and 84 were 84% and 100%, respectively. At day 84, 100% of patients achieved complete cytogenetic remission, 89% achieved measurable residual disease negativity (<0.01%) by multicolor flow cytometry, and 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively. Dual BCR::ABL1 inhibition with dasatinib and asciminib is safe with encouraging activity in patients with de novo Ph+ ALL. This trial was registered at www.clinicaltrials.gov as #NCT02081378.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025. PMID: 39374521. doi:10.1182/blood.2024025800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。